LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Kip Crecca to its Scientific Advisory Board.

“We are thrilled to appoint Kip to our Scientific Advisory Board. He adds to our team a wealth of knowledge and experience as a top medical device sales professional,” said Adam Levy, NEXGEL’s CEO. “Mr. Crecca will be invaluable to the Company as we advance our medical device and healthcare programs. He is an important addition to our group of entrepreneurial individuals with complementary skills and a shared, innovative outlook to drive growth initiatives and continue to better help patients with our hydrogels around the world.”

Mr. Crecca commented, “I am excited to join NEXGEL’s Scientific Advisory Board and collaborate with a talented group of individuals to support the development of new therapies leveraging the Company’s ultra-gentle, high-water-content hydrogels.”

Mr. Crecca brings over two decades of medical device sales and management experience. He currently serves as the VP of North America Sales at MicroSurgical Technology, a leader in the development of advanced surgical instruments and solutions, as well as sitting on the Board of Directors at Ocular Science, a biotech company focused on cost-effective, innovative eye care products. Prior to his current roles, Mr. Crecca served in various sales leadership positions at companies including STAAR Surgical, Abbott Medical Optics, Stryker Endoscopy, and more.

About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal^?, Hexagels^?, Turfguard^?, Kenkoderm^? and Silly George^?. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2022, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at https://www.sec.gov/.